Royce & Associates LP Sells 205,441 Shares of Ironwood Pharmaceuticals, Inc. $IRWD

Royce & Associates LP decreased its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 40.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 300,619 shares of the biotechnology company’s stock after selling 205,441 shares during the period. Royce & Associates LP’s holdings in Ironwood Pharmaceuticals were worth $394,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of IRWD. Merit Financial Group LLC lifted its position in shares of Ironwood Pharmaceuticals by 17.4% during the 3rd quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 7,232 shares during the last quarter. Rhumbline Advisers increased its holdings in Ironwood Pharmaceuticals by 3.5% in the 3rd quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company’s stock worth $292,000 after acquiring an additional 7,611 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in Ironwood Pharmaceuticals by 43.5% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 72,706 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 22,029 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Ironwood Pharmaceuticals by 23.1% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 154,388 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 28,928 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Ironwood Pharmaceuticals during the third quarter valued at about $48,000.

Ironwood Pharmaceuticals Stock Down 3.6%

Shares of Ironwood Pharmaceuticals stock opened at $3.49 on Friday. The company’s fifty day simple moving average is $4.32 and its two-hundred day simple moving average is $2.91. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.53 and a 12-month high of $5.78. The firm has a market cap of $567.75 million, a PE ratio of 26.85 and a beta of 0.24.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.03). The company had revenue of $47.71 million during the quarter, compared to the consensus estimate of $86.10 million. Ironwood Pharmaceuticals had a negative return on equity of 13.72% and a net margin of 8.11%. As a group, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IRWD. Wall Street Zen cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Citizens Jmp raised their target price on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $4.93.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.